Exploring Advanced Renal Cell Carcinoma: Expert and Patient Perspectives : Episode 4

Navigating a Diagnosis of RCC

December 7, 2023

By Thomas E. Hutson, DO, PharmD
Kacie Ellis, RN

Opinion

Video

After his initial fear, Mr. Fuentes educated himself extensively on cancer to understand his diagnosis, which along with having a treatment plan in place, specialist referrals, and tolerable side effects, helps him maintain a positive mindset and manageable quality of life with stage 4 disease.

EP: 1.Overview of Renal Cell Carcinoma (RCC)

EP: 2.Diagnosis and Risk Stratification of Patients With RCC

EP: 3.A Patient’s Experience With an RCC Diagnosis

EP: 4.Navigating a Diagnosis of RCC

EP: 5.The Role of Registered Nurses in the Multidisciplinary Treatment of Advanced RCC

EP: 6.A Patient’s Experience With Initial Treatment for RCC

EP: 7.Overview of the Systemic Treatment Options for Advanced RCC

EP: 8.Educating Patients With Advanced RCC on Side Effects of Available Combination Therapies

EP: 9.A Patient’s Experience With Managing Side Effects of Treatment for Advanced RCC

EP: 10.Future Perspectives in the Management of RCC

EP: 11.Advice for Patients Living With RCC

EP: 12.Patient's Perspective on Pembrolizumab/Lenvatinib Use in RCC

Recent Videos

Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.

Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.

Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.

Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.

Leveraging novel agents, innovative clinical trial designs, and correlative studies may improve the treatment of patients with kidney cancer.

An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.

Kidney cancer advocacy efforts have spread the urgency and importance of funding research in the field to members of Congress.

Advocacy efforts have yielded a dramatic increase in kidney cancer research, according to Elizabeth P. Henske, MD.

A review of patients with metastatic clear cell renal cell carcinoma shows radiological tumor burden as an independent prognostic factor for survival.

Related Content

A prospective trial established that 97% of patients were successfully discharged on the same day as receiving robotic partial nephrectomy.

Outpatient Robotic Partial Nephrectomy Is Safe/Feasible for Renal Tumors

Roman Fabbricatore

April 29th 2025

A prospective trial established that 97% of patients were successfully discharged on the same day as receiving robotic partial nephrectomy.

Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

Manojkumar Bupathi, MD, MS;Manojkumar Bupathi, MD, MS

Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.

Fruquintinib/Sintilimab Meets PFS End Point in Advanced or Metastatic RCC

Fruquintinib/Sintilimab Meets PFS End Point in Advanced or Metastatic RCC

March 19th 2025

Fruquintinib plus sintilimab improved PFS, ORR, and DOR compared with axitinib or everolimus monotherapy in RCC in the phase 2/3 FRUSICA-2 trial.

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

Longer progression-free survival and more enduring responses occurred with avelumab/axitinib vs sunitinib in the phase 3 JAVELIN Renal 101 trial.

Avelumab Combo Improves Long-Term Efficacy Vs Sunitinib in Advanced RCC

February 26th 2025

Longer progression-free survival and more enduring responses occurred with avelumab/axitinib vs sunitinib in the phase 3 JAVELIN Renal 101 trial.

LITESPARK-004 and LITESPARK-005 trial results support the approval of belzutifan in patients with associated localized or advanced clear cell RCC.

Belzutifan Receives European Approval in Localized/Advanced RCC Indications

Roman Fabbricatore

February 18th 2025

LITESPARK-004 and LITESPARK-005 trial results support the approval of belzutifan in patients with associated localized or advanced clear cell RCC.

Related Content

A prospective trial established that 97% of patients were successfully discharged on the same day as receiving robotic partial nephrectomy.

Outpatient Robotic Partial Nephrectomy Is Safe/Feasible for Renal Tumors

Roman Fabbricatore

April 29th 2025

A prospective trial established that 97% of patients were successfully discharged on the same day as receiving robotic partial nephrectomy.

Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

Manojkumar Bupathi, MD, MS;Manojkumar Bupathi, MD, MS

Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.

Fruquintinib/Sintilimab Meets PFS End Point in Advanced or Metastatic RCC

Fruquintinib/Sintilimab Meets PFS End Point in Advanced or Metastatic RCC

March 19th 2025

Fruquintinib plus sintilimab improved PFS, ORR, and DOR compared with axitinib or everolimus monotherapy in RCC in the phase 2/3 FRUSICA-2 trial.

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

Longer progression-free survival and more enduring responses occurred with avelumab/axitinib vs sunitinib in the phase 3 JAVELIN Renal 101 trial.

Avelumab Combo Improves Long-Term Efficacy Vs Sunitinib in Advanced RCC

February 26th 2025

Longer progression-free survival and more enduring responses occurred with avelumab/axitinib vs sunitinib in the phase 3 JAVELIN Renal 101 trial.

LITESPARK-004 and LITESPARK-005 trial results support the approval of belzutifan in patients with associated localized or advanced clear cell RCC.

Belzutifan Receives European Approval in Localized/Advanced RCC Indications

Roman Fabbricatore

February 18th 2025

LITESPARK-004 and LITESPARK-005 trial results support the approval of belzutifan in patients with associated localized or advanced clear cell RCC.

OncNursingNews.com

TargetedOnc.com

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.